IBM will no longer offer, develop, or research facial recognition technology
By Jay Peters,
The Verge
| 06. 08. 2020
IBM’s CEO says we should reevaluate selling the technology to law enforcement
IBM will no longer offer general purpose facial recognition or analysis software, IBM CEO Arvind Krishna said in a letter to Congress today. The company will also no longer develop or research the technology, IBM tells The Verge. Krishna addressed the letter to Sens. Cory Booker (D-NJ) and Kamala Harris (D-CA) and Reps. Karen Bass (D-CA), Hakeem Jeffries (D-NY), and Jerrold Nadler (D-NY).
“IBM firmly opposes and will not condone uses of any [facial recognition] technology, including facial recognition technology offered by other vendors, for mass surveillance, racial profiling, violations of basic human rights and freedoms, or any purpose which is not consistent with our values and Principles of Trust and Transparency,” Krishna said in the letter. “We believe now is the time to begin a national dialogue on whether and how facial recognition technology should be employed by domestic law enforcement agencies.”
Facial recognition software has improved greatly over the last decade thanks to advances in artificial intelligence. At the same time, the technology — because it is often provided by private companies with little regulation...
Related Articles
Flag of South Africa; design by Frederick Brownell,
image by WikimediaCommons users.
Public domain, via Wikimedia Commons
What is the legal status of heritable human genome editing (HHGE)? In 2020, a comprehensive policy analysis by Baylis, Darnovsky, Hasson, and Krahn documented that more than 70 countries and an international treaty prohibit it, and that no country explicitly permits it. Policies in some countries were non-existent, ambiguous, or subject to possible amendment, but the general rule remained, even after one...
By Bernice Lottering, Gene Online | 11.08.2024
South Africa’s updated health-research ethics guidelines, which now include heritable human genome editing, have sparked concern among scientists. The revisions, made in May but only recently gaining attention, outline protocols for modifying genetic material in sperm, eggs, or embryos—changes that...
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...